Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections

Thomas Geisbert, Lisa E. Hensley, Joan B. Geisbert, Peter B. Jahrling

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The neutralizing and enhancing activities of Ebola virus (EBOV)-specific antibodies were tested among four murine antibodies specific to the surface glycoprotein (GP), a recombinant human monoclonal antibody specific to GP, a polyclonal equine IgG, and serum obtained from a convalescent monkey. All but one of these antibodies neutralized EBOV infectivity of primary human monocytes/macrophages or Vero cells. None of the antibodies enhanced EBOV infectivity in these cells. Taken together with in vivo observations that early deaths were not observed in animals immunized with various viral vectors expressing EBOV GP, it is unlikely that any EBOV-enhancing antibodies profoundly affected EBOV pathogenesis.

Original languageEnglish (US)
Pages (from-to)15-19
Number of pages5
JournalVirology
Volume293
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Ebolavirus
Blocking Antibodies
Antibodies
Glycoproteins
Vero Cells
Membrane Glycoproteins
Horses
Haplorhini
Monocytes
Immunoglobulin G
Macrophages
Monoclonal Antibodies
Serum

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. / Geisbert, Thomas; Hensley, Lisa E.; Geisbert, Joan B.; Jahrling, Peter B.

In: Virology, Vol. 293, No. 1, 2002, p. 15-19.

Research output: Contribution to journalArticle

Geisbert, Thomas ; Hensley, Lisa E. ; Geisbert, Joan B. ; Jahrling, Peter B. / Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. In: Virology. 2002 ; Vol. 293, No. 1. pp. 15-19.
@article{3550876b30914e80be97fe9e0cdca6ca,
title = "Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections",
abstract = "The neutralizing and enhancing activities of Ebola virus (EBOV)-specific antibodies were tested among four murine antibodies specific to the surface glycoprotein (GP), a recombinant human monoclonal antibody specific to GP, a polyclonal equine IgG, and serum obtained from a convalescent monkey. All but one of these antibodies neutralized EBOV infectivity of primary human monocytes/macrophages or Vero cells. None of the antibodies enhanced EBOV infectivity in these cells. Taken together with in vivo observations that early deaths were not observed in animals immunized with various viral vectors expressing EBOV GP, it is unlikely that any EBOV-enhancing antibodies profoundly affected EBOV pathogenesis.",
author = "Thomas Geisbert and Hensley, {Lisa E.} and Geisbert, {Joan B.} and Jahrling, {Peter B.}",
year = "2002",
doi = "10.1006/viro.2001.1279",
language = "English (US)",
volume = "293",
pages = "15--19",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections

AU - Geisbert, Thomas

AU - Hensley, Lisa E.

AU - Geisbert, Joan B.

AU - Jahrling, Peter B.

PY - 2002

Y1 - 2002

N2 - The neutralizing and enhancing activities of Ebola virus (EBOV)-specific antibodies were tested among four murine antibodies specific to the surface glycoprotein (GP), a recombinant human monoclonal antibody specific to GP, a polyclonal equine IgG, and serum obtained from a convalescent monkey. All but one of these antibodies neutralized EBOV infectivity of primary human monocytes/macrophages or Vero cells. None of the antibodies enhanced EBOV infectivity in these cells. Taken together with in vivo observations that early deaths were not observed in animals immunized with various viral vectors expressing EBOV GP, it is unlikely that any EBOV-enhancing antibodies profoundly affected EBOV pathogenesis.

AB - The neutralizing and enhancing activities of Ebola virus (EBOV)-specific antibodies were tested among four murine antibodies specific to the surface glycoprotein (GP), a recombinant human monoclonal antibody specific to GP, a polyclonal equine IgG, and serum obtained from a convalescent monkey. All but one of these antibodies neutralized EBOV infectivity of primary human monocytes/macrophages or Vero cells. None of the antibodies enhanced EBOV infectivity in these cells. Taken together with in vivo observations that early deaths were not observed in animals immunized with various viral vectors expressing EBOV GP, it is unlikely that any EBOV-enhancing antibodies profoundly affected EBOV pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0036348849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036348849&partnerID=8YFLogxK

U2 - 10.1006/viro.2001.1279

DO - 10.1006/viro.2001.1279

M3 - Article

VL - 293

SP - 15

EP - 19

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -